| Autor: |
Slotta JE; Jan Erik Slotta, Otto Kollmar, B Michael Ghadimi, Kia Homayounfar, Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, D-37075 Goettingen, Germany., Kollmar O; Jan Erik Slotta, Otto Kollmar, B Michael Ghadimi, Kia Homayounfar, Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, D-37075 Goettingen, Germany., Ellenrieder V; Jan Erik Slotta, Otto Kollmar, B Michael Ghadimi, Kia Homayounfar, Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, D-37075 Goettingen, Germany., Ghadimi BM; Jan Erik Slotta, Otto Kollmar, B Michael Ghadimi, Kia Homayounfar, Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, D-37075 Goettingen, Germany., Homayounfar K; Jan Erik Slotta, Otto Kollmar, B Michael Ghadimi, Kia Homayounfar, Department of General, Visceral and Pediatric Surgery, University Medical Center Goettingen, D-37075 Goettingen, Germany. |
| Abstrakt: |
Hepatocellular carcinoma (HCC) is the most common liver-derived malignancy with a high fatality rate. Risk factors for the development of HCC have been identified and are clearly described. However, due to the lack of tumor-specific symptoms, HCC are diagnosed at progressed tumor stages in most patients, and thus curative therapeutic options are limited. The focus of this review is on surgical therapeutic options which can be offered to patients with HCC with special regard to recent findings, not exclusively focused on surgical therapy, but also to other treatment modalities. Further, potential promising future perspectives for the treatment of HCC are discussed. |
